{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:51:21Z","timestamp":1778003481685,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00259-020-05081-6","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T06:02:26Z","timestamp":1604124146000},"page":"1550-1559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Physiologic colonic uptake of 18F-FDG on PET\/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors"],"prefix":"10.1007","volume":"48","author":[{"given":"Lena","family":"Cvetkovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudine","family":"R\u00e9gis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corentin","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Derosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Malo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meriem","family":"Messaoudene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Desilets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiam","family":"Belkaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arielle","family":"Elkrief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Routy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Juneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"key":"5081_CR1","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","volume":"35","author":"L Horn","year":"2017","unstructured":"Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab versus docetaxel in previously treated patients with advanced non\u2013small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35:3924\u201333. https:\/\/doi.org\/10.1200\/JCO.2017.74.3062.","journal-title":"J Clin Oncol"},{"key":"5081_CR2","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1507643.","journal-title":"N Engl J Med"},{"key":"5081_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer. N Engl J Med. 2015;373:123\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1504627.","journal-title":"N Engl J Med"},{"key":"5081_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0140-6736(16)32517-x","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255\u201365. https:\/\/doi.org\/10.1016\/s0140-6736(16)32517-x.","journal-title":"Lancet."},{"key":"5081_CR5","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/s1470-2045(19)30407-3","volume":"20","author":"SJ Antonia","year":"2019","unstructured":"Antonia SJ, Borghaei H, Ramalingam SS, Horn L, De Castro CJ, Pluzanski A, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019;20:1395\u2013408. https:\/\/doi.org\/10.1016\/s1470-2045(19)30407-3.","journal-title":"Lancet Oncol"},{"key":"5081_CR6","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"key":"5081_CR7","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1810865.","journal-title":"N Engl J Med"},{"key":"5081_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3747\/co.27.5953","volume":"27","author":"A Elkrief","year":"2020","unstructured":"Elkrief A, Joubert P, Florescu M, Tehfe M, Blais N, Routy B. Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020. Curr Oncol. 2020;27:52\u201360. https:\/\/doi.org\/10.3747\/co.27.5953.","journal-title":"Curr Oncol"},{"key":"5081_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/s0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540\u201350. https:\/\/doi.org\/10.1016\/s0140-6736(15)01281-7.","journal-title":"Lancet."},{"key":"5081_CR10","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.ccr-18-1538","volume":"25","author":"DB Doroshow","year":"2019","unstructured":"Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in non\u2013small cell lung cancer: facts and hopes. Clin Cancer Res. 2019;25:4592\u2013602. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-1538.","journal-title":"Clin Cancer Res"},{"key":"5081_CR11","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288\u2013301. https:\/\/doi.org\/10.1056\/NEJMoa1716948.","journal-title":"N Engl J Med"},{"key":"5081_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer. Science. 2015;348:124\u20138. https:\/\/doi.org\/10.1126\/science.aaa1348.","journal-title":"Science."},{"key":"5081_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91\u20137. https:\/\/doi.org\/10.1126\/science.aan3706.","journal-title":"Science."},{"key":"5081_CR14","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368\u201379. https:\/\/doi.org\/10.1093\/annonc\/mdx108.","journal-title":"Ann Oncol"},{"key":"5081_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236.","journal-title":"Science."},{"key":"5081_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104\u20138. https:\/\/doi.org\/10.1126\/science.aao3290.","journal-title":"Science."},{"key":"5081_CR17","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","volume":"14","author":"Y Jin","year":"2019","unstructured":"Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen Y, et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. J Thorac Oncol. 2019;14:1378\u201389. https:\/\/doi.org\/10.1016\/j.jtho.2019.04.007.","journal-title":"J Thorac Oncol"},{"key":"5081_CR18","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/annonc\/mdz206","volume":"30","author":"A Elkrief","year":"2019","unstructured":"Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann Oncol. 2019;30:1572\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdz206.","journal-title":"Ann Oncol"},{"key":"5081_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00262-019-02453-2","volume":"69","author":"BE Wilson","year":"2020","unstructured":"Wilson BE, Routy B, Nagrial A, Chin VT. The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. Cancer Immunol Immunother. 2020;69:343\u201354. https:\/\/doi.org\/10.1007\/s00262-019-02453-2.","journal-title":"Cancer Immunol Immunother"},{"key":"5081_CR20","doi-asserted-by":"publisher","first-page":"e1568812","DOI":"10.1080\/2162402X.2019.1568812","volume":"8","author":"A Elkrief","year":"2019","unstructured":"Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, et al. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. Oncoimmunology. 2019;8:e1568812. https:\/\/doi.org\/10.1080\/2162402X.2019.1568812.","journal-title":"Oncoimmunology."},{"key":"5081_CR21","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","volume":"5","author":"DJ Pinato","year":"2019","unstructured":"Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5:1774\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2785.","journal-title":"JAMA Oncol"},{"key":"5081_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.eururo.2020.04.044","volume":"78","author":"L Derosa","year":"2020","unstructured":"Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur Urol. 2020;78:195\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2020.04.044.","journal-title":"Eur Urol"},{"key":"5081_CR23","doi-asserted-by":"publisher","unstructured":"Hakozaki T, Richard C, Elkrief A, Hosomi Y, Benla\u00effaoui M, Mimpen I, et al. The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non\u2013small cell lung cancer. Cancer Immunol Res. 2020; 8:1243\u20131250. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0196.","DOI":"10.1158\/2326-6066.CIR-20-0196"},{"key":"5081_CR24","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1210\/jc.2015-4251","volume":"101","author":"KM Utzschneider","year":"2016","unstructured":"Utzschneider KM, Kratz M, Damman CJ, Hullar M. Mechanisms linking the gut microbiome and glucose metabolism. J Clin Endocrinol Metab. 2016;101:1445\u201354. https:\/\/doi.org\/10.1210\/jc.2015-4251.","journal-title":"J Clin Endocrinol Metab"},{"key":"5081_CR25","doi-asserted-by":"publisher","first-page":"e0192747","DOI":"10.1371\/journal.pone.0192747","volume":"13","author":"B Boursi","year":"2018","unstructured":"Boursi B, Werner TJ, Gholami S, Houshmand S, Mamtani R, Lewis JD, et al. Functional imaging of the interaction between gut microbiota and the human host: a proof-of-concept clinical study evaluating novel use for 18F-FDG PET-CT. PLoS One. 2018;13:e0192747. https:\/\/doi.org\/10.1371\/journal.pone.0192747.","journal-title":"PLoS One"},{"key":"5081_CR26","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1148\/rg.284075203","volume":"28","author":"B Bybel","year":"2008","unstructured":"Bybel B, Brunken RC, DiFilippo FP, Neumann DR, Wu G, Cerqueira MD. SPECT\/CT imaging: clinical utility of an emerging technology. Radiographics. 2008;28:1097\u2013113. https:\/\/doi.org\/10.1148\/rg.284075203.","journal-title":"Radiographics."},{"key":"5081_CR27","unstructured":"Dore J, Ehrlich SD, Levenez F, Pelletier E, Alberti A, Bertrand L and IHMS Consortium (2015). IHMS_SOP 05 V1: Standard operating procedure forfecal samples preserved in stabilizing solution self\u2010collection, laboratory analysis handled within 24 hours to 7 days (24 hours \u02c2 x \u2264 7 days). International Human Microbiome Standards. 2015. http:\/\/www.microbiome-standards.org. Accessed March 5th, 2020."},{"key":"5081_CR28","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1128\/AEM.65.11.4799-4807.1999","volume":"65","author":"A Suau","year":"1999","unstructured":"Suau A, Bonnet R, Sutren M, Godon J-J, Gibson GR, Collins MD, et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol. 1999;65:4799\u2013807.","journal-title":"Appl Environ Microbiol"},{"key":"5081_CR29","doi-asserted-by":"publisher","unstructured":"Visconti A, Martin TC, Falchi M. YAMP: a containerized workflow enabling reproducibility in metagenomics research. Gigascience. 2018;7:1\u20139. https:\/\/doi.org\/10.1093\/gigascience\/giy072.","DOI":"10.1093\/gigascience\/giy072"},{"key":"5081_CR30","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nmeth.2066","volume":"9","author":"N Segata","year":"2012","unstructured":"Segata N, Waldron L, Ballarini A, Narasimhan V, Jousson O, Huttenhower C. Metagenomic microbial community profiling using unique clade-specific marker genes. Nat Methods. 2012;9:811\u20134. https:\/\/doi.org\/10.1038\/nmeth.2066.","journal-title":"Nat Methods"},{"key":"5081_CR31","doi-asserted-by":"publisher","first-page":"e61217","DOI":"10.1371\/journal.pone.0061217","volume":"8","author":"PJ McMurdie","year":"2013","unstructured":"McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One. 2013;8:e61217. https:\/\/doi.org\/10.1371\/journal.pone.0061217.","journal-title":"PLoS One"},{"key":"5081_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2307\/1942268","volume":"27","author":"JR Bray","year":"1957","unstructured":"Bray JR, Curtis TJ. An ordination of upland forest communities of southern Wisconsin. Ecol Monogr. 1957;27:325\u201349. https:\/\/doi.org\/10.2307\/1942268.","journal-title":"Ecol Monogr"},{"key":"5081_CR33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1534\/genetics.108.098863","volume":"182","author":"C Zhu","year":"2009","unstructured":"Zhu C, Yu J. Nonmetric multidimensional scaling corrects for population structure in association mapping with different sample types. Genetics. 2009;182:875\u201388. https:\/\/doi.org\/10.1534\/genetics.108.098863.","journal-title":"Genetics."},{"key":"5081_CR34","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol"},{"key":"5081_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"5081_CR36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381. https:\/\/doi.org\/10.1080\/01621459.1958.10501452.","journal-title":"J Am Stat Assoc"},{"key":"5081_CR37","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163\u201370.","journal-title":"Cancer Chemother Rep"},{"key":"5081_CR38","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nature11550","volume":"489","author":"CA Lozupone","year":"2012","unstructured":"Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220\u201330. https:\/\/doi.org\/10.1038\/nature11550.","journal-title":"Nature."},{"key":"5081_CR39","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nature05414","volume":"444","author":"PJ Turnbaugh","year":"2006","unstructured":"Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027\u201331. https:\/\/doi.org\/10.1038\/nature05414.","journal-title":"Nature."},{"key":"5081_CR40","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/ni.3780","volume":"18","author":"JM Blander","year":"2017","unstructured":"Blander JM, Longman RS, Iliev ID, Sonnenberg GF, Artis D. Regulation of inflammation by microbiota interactions with the host. Nat Immunol. 2017;18:851\u201360. https:\/\/doi.org\/10.1038\/ni.3780.","journal-title":"Nat Immunol"},{"key":"5081_CR41","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/cmr.0000000000000566","volume":"29","author":"B Boursi","year":"2019","unstructured":"Boursi B, Werner TJ, Gholami S, Margalit O, Baruch E, Markel G, et al. Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma. Melanoma Res. 2019;29:318\u201321. https:\/\/doi.org\/10.1097\/cmr.0000000000000566.","journal-title":"Melanoma Res"},{"key":"5081_CR42","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M Vetizou","year":"2015","unstructured":"Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079\u201384. https:\/\/doi.org\/10.1126\/science.aad1329.","journal-title":"Science."},{"key":"5081_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","volume":"7","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019;7:193. https:\/\/doi.org\/10.1186\/s40425-019-0650-9.","journal-title":"J Immunother Cancer"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05081-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-020-05081-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05081-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T08:16:32Z","timestamp":1620720992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-020-05081-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["5081"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-05081-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,31]]},"assertion":[{"value":"15 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DJ has received consultant fees from AbbVie and Advanced Accelerator Applications. BR reports acting as a Scientific Advisory Board Member for Vedanta. All other authors have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Ethics Committee (Ethics number CER CHUM: 18.039 and 18.085-17.035) and conducted in accordance with the tenets of the Declaration of Helsinki. The need for informed patient consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}